[{"id":"6e8fbd0c-23f7-46c6-93fc-7a144127a44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05764395","created_at":"2023-03-10T15:01:42.443Z","updated_at":"2024-07-02T16:34:36.730Z","phase":"Phase 2","brief_title":"Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors","source_id_and_acronym":"NCT05764395","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Estybon (rigosertib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-10"},{"id":"bccdf47b-f667-4740-8dce-142e2428e515","acronym":"","url":"https://clinicaltrials.gov/study/NCT04263090","created_at":"2021-01-18T20:43:01.463Z","updated_at":"2025-02-25T14:29:03.672Z","phase":"Phase 1/2","brief_title":"Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment","source_id_and_acronym":"NCT04263090","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Estybon (rigosertib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-09"},{"id":"8b936338-8214-4e74-b918-526c622c7c6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00861328","created_at":"2021-01-18T03:17:03.343Z","updated_at":"2024-07-02T16:37:20.692Z","phase":"Phase 1","brief_title":"Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin","source_id_and_acronym":"NCT00861328","lead_sponsor":"Onconova Therapeutics, Inc.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Estybon (rigosertib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2017-06-23"}]